Funding
Funding not disclosed
Founders
Product
Problem
Current treatment options for aggressive cancers and drug‑resistant infections are limited, and developing new therapeutics is hampered by lengthy discovery cycles and insufficient specificity of existing modalities.
Solution
Solstar Pharma leverages a precision siRNA platform to design nucleic acid medicines that selectively silence disease‑causing genes. The platform enables rapid identification and optimization of siRNA sequences targeting pathogens or oncogenic drivers, producing pre‑clinical candidates with high potency and reduced off‑target effects. By focusing on anti‑infective and anti‑cancer applications, Solstar creates proprietary intellectual property aimed at unmet medical needs, accelerating the transition from concept to in‑vivo validation.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking licensed siRNA‑based drug candidates for infectious disease or oncology programs, as well as research institutions pursuing collaborative development of novel nucleic acid therapeutics.
Features
- Proprietary siRNA design pipeline that integrates computational modeling and empirical screening to select highly specific gene‑silencing candidates
- Chemical modification and formulation strategies that enhance siRNA stability, cellular uptake, and tissue targeting
- Platform capability to generate both anti‑infective agents against resistant microbes and anti‑cancer therapeutics for aggressive tumor types
- Pre‑clinical development workflow that includes in‑vitro efficacy assays, pharmacokinetic profiling, and animal model validation
- Generation of protected intellectual property around each siRNA therapeutic candidate